Strategies to enhance covalent chimera/inhibitor protein labeling kinetics typically include optimizing electrophile preorganization or enhancing the ligand binding affinity. For targeting sugars binding receptors using cARMs, however, these approaches are likely to require extensive medicinal chemistry to yield only modest improvements that are applicable to only a subset of polyclonal antirhamnose antibodies. much less favorableKIassociated with carbohydrateprotein binding relationships can be offset by a favorably largekinactfor the covalent labeling step. In the current study, we test this hypothesis in the context of a model system that uses rhamnose-specific antibodies to induce tumor-immune proximity and tumoricidal function. We discovered that synthetic chimeric molecules capable of preorganizing an ideal electrophile (i.e., SuFEx vs triggered ester) for protein engagement can rapidly covalently engage natural sources of antirhamnose antibody using only a single low-affinity rhamnose monosaccharide ABD. Strikingly, we observe chimeric molecules lacking Benzydamine HCl an electrophile, which can only noncovalently bind the antibody, completely lack tumoricidal function. This is in stark contrast to earlier work focusing on Benzydamine HCl small molecule hapten and peptide-specific antibodies. Our findings underscore the power of covalency as a strategy to engage low-affinity carbohydrate-specific proteins for tumor-immune proximity induction. == Short abstract == We demonstate that heterobifunctional electrophilic molecules can covalently participate carbohydrate-specific proteins for tumor immunotherapy, leveraging only simple low-affinity sugars. == Intro == Carbohydrates play an essential role in many immunological functions through the specific engagement of receptors like lectins and anti-carbohydrate antibodies. For example, the mannose receptor (CD206) on macrophages recognizes mannose/fucose on pathogenic focuses on, leading to phagocytosis, and is a marker for macrophage polarization (CD206 overexpressed on M2-like tumor-associated macrophages).14Dectin 1/2 receptors largely recognize -glucans and mannose residues, respectively, to potentiate inflammatory antipathogenic reactions.512Furthermore, dendritic cell-specific ICAM-3 grabbing nonintegrin (DC-SIGN), largely expressed on dendritic cells, is associated with antigen uptake and ITGAE subsequent MHC demonstration for the potentiation of adaptive immune reactions.1317Alternatively, soluble carbohydrate binding proteins such as mannose-binding lectin and anti-carbohydrate antibodies play crucial roles in immune defenses against pathogens.1821For example, the PPV23 vaccine induces anticarbohydrate antibodies to protect against a variety of streptococcus pneumonia serotypes (e.g., induction of -l-rhamnose specific antibodies realizing the 23F serotype).2224 Several bifunctional proximity-inducing25,26therapeutic strategies function through the highly stabilized engagement of carbohydrate binding receptors. One strategy uses lysosome focusing on chimeras (LYTACs), which integrate a tumor-targeting antibody having a multivalent array of GalNac and M6Pn sugars.27,28The simultaneous engagement of ASGPR or CI-M6PR and the prospective leads to endocytosis and lysosome accumulation/degradation of the cell surface or soluble target proteins. Notably, analogous nonantibody-based methods have also been reported.29,30 A second strategy uses monoclonal antibodies (mAbs) which function by simultaneously binding both tumor antigens (via their Fab domain) and sugar-specific immune receptors (via their glycosylated Fc domain).3135Upon reaching a critical threshold of antibodies localized to the prospective surface (opsonization), subsequent engagement of immune parts (i.e. tumor-immune proximity induction) can affect target removal via complement-dependent Benzydamine HCl cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), or antibody-dependent cellular phagocytosis (ADCP). In fact, glyco-engineering the mAb glycan at position Asn297 can distinctively increase antitumor function by increasing antibody glycan binding affinity for Fc receptors.3641For Benzydamine HCl example, defucosylation can stabilize glycan CD16 interactions, leading to enhanced ADCC.42,43 A third strategy uses multivalent macromolecular chimeric scaffolds to engage endogenous serum antirhamnose antibodies for tumor-immune proximity induction (Plan1). Here Benzydamine HCl a synthetic scaffold is equipped with both a tumor binding website (TBD) and a multivalent array of rhamnose sugars, providing as an antibody binding website (ABD). For example, Coen et al. used a rhamnose-decorated polymer lipid anchored into cells, while Liet et al. shown that dendrimeric rhamnose conjugates can bridge antirhamnose antibodies with target cells.44,45Alternatively, Sheridan et al., Jakobsche et al., and Goyard et al. shown antirhamnose-induced CDC of target cells through artificial multivalent rhamnose arrays on target cells (via lipid-anchored rhamnose, rhamnose-NHS-mediated cell surface labeling, or metabolic labeling to incorporate dendrimeric rhamnose, respectively).4648Interestingly, Li et al. used rhamnose- and folic acid-functionalized liposomes to induce targeted CDC in vitro and tumor regression in vivo.49 == Plan 1. Founded and Current/Growing Chemical Strategies to Induce Tumor-Immune Proximity via Carbohydrate-Specific Antibodies. == Left panel: figure story plus previous work using non-covalent monovalent.